Highlights

- Biocon initiates Phase 1 Clinical Trials in Europe after getting   approvals from the MPA (Sweden), 2007

- Biocon initiates clinical trial of T1h in Rheumatoid Arthritis,   2007

- Additional clinical trials for use of BIOMAb EGFR™ in the   treatment of glioma and non-small cell lung carcinoma   initiated, 2007

- Biocon unveils five renal therapy drugs, 2007

- Biocon gets regulatory approval for GCSF, 2007

- Biocon gets regulatory approval for Streptokinase, 2007

- Biocon signs pact with Deakin University to jointly develop a   mammalian cell bio-processing facility, 2007

- Biocon files PCT for novel process of manufacturing of Oral   Insulin, 2006

- Biocon completes phase-IV trials of INSUGEN®, 2006

- Biocon launches BIOMAb-EGFR™, a therapeutic monoclonal   antibody-based drug for treating solid tumors of epithelial   origin, 2006

- Biocon acquires the intellectual property of Nobex Corporation.   With it, Biocon's total IP estate increases by nearly 300 patents   and patent applications focused on oral peptide therapeutics in   the metabolic and cardiovascular segment, 2005

- Biocon and Karolinska Institute sign a MoU to collaborate in   research and research education initiatives, 2005

- Biocon and Vaccinex partner to discover and develop   therapeutic antibodies, 2004

- Biocon launches INSUGEN®, the world's first recombinant   human (r-DNA) insulin using a unique Pichia expression system,   2004

- Biocon files its 100th patent application, July 2003

- Biocon ranks 3rd among Indian companies for filing PCT   applications, 2002

- Biocon files PCT application for patent on 'Methods of   producing esters of Mycophenolate'

- US patent office grants 3 patents on the process for the    manufacture of Simvastatin

- FDA approves a solid state process for the manufacture of   Lovastatin

- US patent office grants a patent on PlaFractor™, Biocon's   revolutionary bioreactor, 2001